This Article Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (39) Citing Articles via Google Scholar Google Scholar Articles by Hillman, A. L. Articles by Ross, R. Search for Related Content PubMed PubMed Citation Articles by Hillman, A. L. Articles by Ross, R. Related Collections Managed Care Health Spending

Health Affairs, Vol 18, Issue 2, 189-200
Copyright © 1999 by Project HOPE

DataWatch

Financial incentives and drug spending in managed care

This study estimates the impact of patient financial incentives on the use and cost of prescription drugs in the context of differing physician payment mechanisms. A large data set was developed that covers persons in managed care who pay varying levels of cost sharing and whose physicians are compensated under two different models: independent practice association (IPA)-model and network-model health maintenance organizations (HMOs). Our results indicate that higher patient copayments for prescription drugs are associated with lower drug spending in IPA models (in which physicians are not at risk for drug costs) but have little effect in network models (in which physicians bear financial risk for all prescribing behavior).

                      What's this?

This article has been cited by other articles:

				D. P. Goldman, G. F. Joyce, and Y. Zheng Prescription Drug Cost Sharing: Associations With Medication and Medical Utilization and Spending and Health JAMA, July 4, 2007; 298(1): 61 - 69. [Abstract] [Full Text] [PDF]

				W. H Shrank, S. M Asch, G. J Joseph, H. N Young, S. L Ettner, Y. Kholodenko, P. Glassman, and R. L Kravitz Physicians' Perceived Knowledge of and Responsibility for Managing Patients' Out-of-Pocket Costs for Prescription Drugs Ann. Pharmacother., September 1, 2006; 40(9): 1534 - 1540. [Abstract] [Full Text] [PDF]

				W. H. Shrank, T. Hoang, S. L. Ettner, P. A. Glassman, K. Nair, D. DeLapp, J. Dirstine, J. Avorn, and S. M. Asch The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med, February 13, 2006; 166(3): 332 - 337. [Abstract] [Full Text] [PDF]

				H. L. Lipton, J. D. Agnew, M. R. Stebbins, A. Kuo, and R. A. Dudley Managing the Unmanageable: The Nature and Impact of Drug Risk in Physician Groups Journal of Health Politics Policy and Law, August 1, 2005; 30(4): 719 - 750. [Abstract] [PDF]

				W. H. Shrank, S. L. Ettner, P. Glassman, and S. M. Asch A Bitter Pill: Formulary Variability and the Challenge to Prescribing Physicians J Am Board Fam Med, November 1, 2004; 17(6): 401 - 407. [Abstract] [Full Text] [PDF]

				J. G. Baker Engaging Community Mental Health Stakeholders in Pharmacy Cost Management Psychiatr Serv, May 1, 2001; 52(5): 650 - 653. [Abstract] [Full Text] [PDF]